Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib
The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.
You may also be interested in...
The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch.
Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.